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This is the second part of a review on nanotechnology in general and particularly as it pertains to drug 
deliver. In the earlier paper (Part 1), nanotechnology in nature, its history as well as design and methods 
were discussed. Its applications, benefits and risks were also outlined. In this paper (Part 2), various 
nanostructures employed in drug delivery, their methods of fabrication and challenges of nano drug 
delivery are reviewed. Nanotechnology is one approach to overcome challenges of conventional drug 
delivery systems based on the development and fabrication of nanostructures. Some challenges 
associated with the technology as it relates to drug effectiveness, toxicity, stability, pharmacokinetics 
and drug regulatory control are discussed in this review. Clearly, nanotechnology is a welcome 
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INTRODUCTION 
 
Nanotechnology by manipulation of 
characteristics of materials such as polymers 
and fabrication of nanostructures is able to 
provide superior drug delivery systems for 
better management and treatment of 
diseases. The nanostructures employed as 
drug delivery systems have multiple 
advantages which make them superior to 
conventional delivery systems. In Part I, the 
advantages of nanostructures in drug delivery 
were outlined. 
 
These benefits account for the extensive 
research that have been undertaken into the 
development of nanostructures such as 
liposomes, nanocapsules, nanoemulsions, 
solid lipid nanoparticles, dendrimers, 
polymeric nanoparticles, etc, for delivery of 
drugs. The materials employed in the 
fabrication of nanostructures determine the 
type of nanostructures obtained and these 
nanostructures, in turn, determine the 
different properties obtained and the release 
characteristics of incorporated drugs. 
 





Polymeric nanoparticles are colloidal solid 
particles with a size range of 10 to 1000nm 
1
 
and they can be spherical, branched or shell 
structures. The first fabrication of 
nanoparticles was about 35 years ago as 
carriers for vaccines and cancer 
chemotherapeutics
2
. They are developed 
from non-biodegradable and biodegradable 
polymers. Their small sizes enable them to 
penetrate capillaries and to be taken up by 
cells, thereby increasing the accumulation of 
drugs at target sites. Drugs are incorporated 
into nanoparticles by dissolution, entrapment, 
adsorption, attachment or by encapsulation, 
and the nanoparticles provide sustained 
release of the drugs for longer periods, e.g., 
days and weeks
3
. Nanoparticles enhance 
immunization by prevention of degradation of 
the vaccine and increased uptake by immune 
cells
4
. One of the determinants of the extent 
of uptake by immune cells is the type of 
polymer employed. In a study
4
 comparing 
poly-(ε-caprolactone) (PCL), poly (lactide-co-
glycolide) (PLGA) and their blend, PCL 
nanoparticles were the most efficiently taken 
up by immune cells due to their 
hydrophobicity. However, all polymeric 
nanoparticles elicited vaccine (diphtheria 
toxoid) specific serum IgG antibody response 
significantly higher than free diphtheria 
toxoid.  
 
To target drugs to site of action, the drug can 
be conjugated to a tissue or cell specific 
ligand or coupled to macromolecules that 
reach the target organs. To target an 
anticancer agent to the liver, polymeric 
conjugate nanoparticles which comprised 
biotin and diamine-terminated poly (ethylene 
glycol) with a galactose moiety from 




Some other applications of nanoparticles 
include possible recognition of vascular 
endothelial dysfunction
6
; oral delivery of 
insulin
7
; brain drug targeting for 
neurodegenerative disorders such as 
Alzheimer’s disease
8
; topical administration 
to enhance penetration and distribution in 
and across the skin barrier
9
; and pH-sensitive 
nanoparticles to improve oral bioavailability of 
drugs such as cyclosporine A 
10
. Some 
polymers used in the fabrication of 
nanoparticles include chitosan, alginate, 
albumin, gelatin, polyacrylates, polycaprol-
actones, poly(D, L-lactide-co-glycolide) and 
poly (D, L-lactide) However, there are 
concerns about polymeric nanoparticles 
including cytotoxicity of by-products (although 
some, such as polyanhydrides, degrade into 





Liposomes were first developed about 40 
years ago
2
. They are small artificial vesicles 
(50 – 100nm) developed from phospholipids 
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such as phosphatidylcholine, phosphatidyl-
glycerol, phosphatidylethanolamine and 
phosphatidylserine, which have been used in 
biology, biochemistry, medicine, food and 
cosmetics
11-14
. The characteristics of 
liposomes are determined by the choice of 
lipid, their composition, method of 
preparation, size and surface charge 
1
. 
Liposomes have been applied as drug 
carriers due to their ability to prevent 
degradation of drugs, reduce side effects and 
target drugs to site of action
15
. However, 
limitations of liposomes include low 
encapsulation efficiency, rapid leakage of 
water-soluble drug in the presence of blood 
components and poor storage stability
15,16
. 
However, surface modification may confer 
stability and structure integrity against harsh 
bio-environment after oral or parenteral 
administration
17
. Surface modification can be 
achieved by attaching polymers such as poly 
(methacrylic acid-co-stearyl methacrylate) 
and polyethylene glycol units to improve the 
circulation time of liposomes in the blood; and 
by conjugation to antibodies or ligands such 





Applications of liposomes include 
transdermal drug delivery to enhance skin 
permeation of drugs with high molecular 
weight and poor water solubility
19
; a carrier 
for delivery of drugs, such as gentamicin, in 
order to reduce toxicity
20
; possible drug 





 and in the treatment of 
parasitic infections. However, solid lipid 
nanoparticles (SLNs) provide an effective 





Other vesicular structures include 
transferosomes, ethosomes, niosomes and 




are developed by incorporation of surfactant 
molecules (edge activators) such as sodium 
chlorate into liposomes while ethosomes are 
liposomes that are high in ethanol (up to 
45%). Niosomes are vesicles developed from 
non-ionic surfactants and marinosomes are 
liposomes produced from a natural marine 
lipid extract containing a high poly 




Dendrimers are nanostructures produced 
from macromolecules such as 
polyamidoamine (PAMAM), polypropylene-
imine and polyaryl ether; and are highly 
branched with an inner core. The particle size 
range is between 1 to 100nm although their 
sizes are mostly less than 10nm. About 20 
years ago, dendrimer studies centred on their 
synthesis, physical and chemical properties 
while exploration of their biological 
applications was initiated about thirteen years 
ago
26
. The uniqueness of dendrimers is 
based on their series of branches, 
multivalency, well defined molecular weight 
and globular structure with controlled surface 
functionality, which enhances their potential 
as carriers for drug delivery
26,27
. Their 
globular structures and the presence of 
internal cavities enable drugs to be 
encapsulated within the macromolecule 
interior. Dendrimers have been reported to 
provide controlled release from the inner 
core
27
. However, drugs are incorporated both 
in the interior as well as attached on the 
surface. Due to their versatility, both 
hydrophilic and hydrophobic drugs can be 
incorporated into dendrimers. 
 
Controlled multivalency of dendrimers 
enables attachment of several drug 
molecules, targeting groups and solubilising 
groups onto the surfaces of the dendrimers in 
a well defined manner
26
. Dendrimers are 
employed due to their size (less than 10nm), 
ease of preparation, functionality and their 
ability to display multiple copies of surface 
groups for biological recognition process
28
.  
Water soluble dendrimers can bind and 
solubilise small molecules and can be used 
as coating agents to protect drugs and deliver 
to specific sites. Other applications of 
dendrimers include catalysis, gene and DNA 
delivery, biomimetics and as solution phase 
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supports for combinatorial chemistry 
29
. Some 
of the drug delivery applications include 
therapeutic and diagnostic utilization for 
cancer treatment
30
; enhancement of drug 
solubility and permeability (dendrimer-drug 
conjugates)
31






Solid lipid nanoparticles (SLN) are 
nanostructures made from solid lipids such 
as glyceryl behenate (Compritol), stearic 
triglyceride (tristearin), cetyl palmitate and 
glycerol tripalmitate (tripalmitin)  with a size 
range of 50 and 1000 nm
33,34
. Research 
interest in SLN emerged about ten years ago 
due to their scalability potential. The lipids 
employed are well tolerated by the body; 
large scale production will be cost effective 
and simple by using high pressure 
homogenization. Some of the features of SLN 
include good tolerability, site-specific 
targeting, stability (stabilized by surfactants or 
polymers), controlled drug release and 
protection of liable drugs from degradation
34
. 
However, SLN are known for insufficient drug 
loading, drug expulsion after polymorphic 
transition on storage and relative high water 
content of the dispersions
34
. SLN has been 
studied and developed for parenteral, dermal, 





To overcome the limitations of SLN, 
nanostructured lipid carriers (NLC) were 
introduced. NLC is composed of solid lipids 
and a certain amount of liquid lipids with 
improved drug loading and increased stability 
on storage thereby reducing drug 
expulsion
34,36
. NLCs have been explored for 





Lipid drug conjugate (LDC) nanoparticles 
were introduced to overcome the limitation of 
types of drugs incorporated in the solid lipid 
matrix. Lipophilic drugs are usually 
incorporated in SLN but due to partitioning 
effects during production, only highly potent 
hydrophilic drugs effective in low 
concentrations are incorporated in SLN
34
. 
LDC enables the incorporation of both 
hydrophilic (e.g., doxorubicin and tobramycin) 





Polymeric micelles  
 
Micelles are formed when amphiphilic 
surfactant or polymeric molecules 
spontaneously associate in aqueous medium 
to form core-shell structures or vesicles. 
Polymeric micelles are formed from 
amphiphilic block copolymers, such as 
poly(ethylene oxide)-poly(β-benzyl-L-
aspartate) and poly(N-isopropylacrylamide)-
polystyrene, and are more stable than 
surfactant micelles in physiological 
solutions
39
. They were first proposed as drug 
carriers about 24 years ago
39
. The inner core 
of a micelle is hydrophobic which is 
surrounded by a shell of hydrophilic polymers 
such as poly (ethylene glycol)
40
. Their 
hydrophobic core enables incorporation of 
poorly water soluble and amphiphilic drugs 
while their hydrophilic shell and size (< 
100nm) prolong their circulation time in the 





Polymeric micelles are able to reach parts of 
the body that are poorly accessible to 
liposomes; accumulate more than free drugs 
in tumoural tissues due to increased vascular 
permeability
39
. Thus, polymeric micelles can 
be employed to administer 
chemotherapeutics in a controlled and 
targeted manner with high concentration in 
the tumoural cells and reduced side effects. 
However, the targeting ability of polymeric 
micelles is limited due to low drug loading
41,42 
and low drug incorporation stability
41
 which 
cause the loaded drug to be released before 
getting to the site of action. Consequently, 
manipulation of the production parameters 
and the design of the inner core can improve 
drug loading and drug incorporation stability, 
respectively
41,42
. Lipid moieties, such as 
cholesterol and fatty acyl carnitines, can also 
be employed to impart good stability to the 
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polymeric micelles. This is based on 
increased hydrophobic interaction between 
the polymeric chains in the inner core due to 





Polymeric micelles have been employed for 
targeted and intracellular delivery
42
, 






Nanocapsules are spherical hollow structures 
in which the drug is confined in the cavity and 
is surrounded by a polymer membrane
43
. 
They were developed over 30 years ago. 
Sizes between 50 and 300nm are preferred 
for drug delivery and they may be filled with 
oil which can dissolve lipophilic drugs. They 
have low density, high loading capacity and 
are taken up by the mononuclear phagocyte 
system, and accumulate at target organs 




Nanocapsules can be employed as confined 
reaction vessels, protective shell for cells or 
enzymes, transfection vectors in gene 
therapy, dye dispersants, carriers in 
heterogenous catalysis, imaging and drug 
carriers
45,46
. They are known to improve the 
oral bioavailability of protein and peptides 
which include insulin, elcatonin and salmon 
calcitonin
43,47
. Encapsulation of drugs such as 
ibuprofen
44
 within nanocapsules protects 
liable drugs from degradation, reduces 
systemic toxicity, provide controlled release 
and mask unpleasant taste
48
. Due to their 
high stability and low permeability, drugs may 
not be loaded into the capsules after 
formulation and also the release of the drug 
at target site may be difficult. To improve on 
their permeability, they are made responsive 
to physiological factors such as pH
49




Nanoemulsions are emulsions with droplet 
size below 1µ but usually between 20 and 
200nm 
50,51
. Unlike microemulsions which are 
white in colour due to their light scattering 
ability, nanoemulsions whose nanosize is 
often smaller than visible wavelength, are 
transparent
50,52
. Nanoemulsions are 
biodegradable, biocompatible, easy to 
produce and used as carriers for lipophilic 
drugs which are prone to hydrolysis. They are 
employed as a sustained release delivery 
system for depot formation via subcutaneous 
injection
51
. They enhance gastrointestinal 
absorption and reduce inter- and intra-subject 
variability for various drugs. Due to their very 
large interfacial area, they exhibit excellent 
drug release profile
53
. Nanoemulsions have 
been studied and developed for parenteral, 





Stability against sedimentation is attained 
based on the nano size of the droplets 
because the sedimentation rate due to gravity 
is less than Brownian movement and 
diffusion
50
. Unlike microemulsions, 
nanoemulsions are metastable and can be 
destabilized by Ostwald ripening whereby the 
small droplets dissolve and their mass is 
taken up by the large droplets and depletion 
induced flocculation due to addition of 
thickening polymers. When this happens, the 
nanoemulsion becomes opaque and 
creaming will occur
54
. However, addition of a 
small amount of a second oil with low 
solubility into the aqueous phase and addition 
of a second surfactant may reduce Ostwald 
ripening
50
. Also, a number of factors during 
production should be controlled
52
. These 
factors include selecting an appropriate 
composition, controlling the order of addition 
of components, applying the shear in a 
manner that will effectively rupture the 
droplets, and ensuring that the dispersed 
phase molecules are insoluble in the 
continuous phase so that Ostwald ripening 






Ceramic nanoparticles are particles 
fabricated from inorganic compounds with 
porous characteristics such as silica, alumina 
and titania
55-57
. They can be prepared with 
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the desired size, shape and porosity. Their 
sizes are less than 100nm and are able to 
avoid uptake by the reticulo-endothelial 
system as foreign bodies. Entrapped 
molecules such as drugs, proteins and 
enzymes are protected from denaturation at 
physiological pH and temperature as neither 
swelling nor change in porosity occurs
57
. 
Hence, they are effective in delivering 
proteins and genes. However, these particles 
are not biodegradable and so there is 
concern that they may accumulate in the 






Metallic nanoparticles include iron oxide, 
gold, silver, gadolinium and nickel which have 
been studied for targeted cellular delivery
58
. 
Gold exhibits favourable optical and chemical 
properties at nanoscale for biomedical 
imaging and therapeutic applications
56
. It can 
be manipulated to obtain the desired size in 
the range of 0.8 to 200nm. The surface can 
be modified with different functional groups 
for gene transfection, modified into gene 
delivery vector by conjugation and also 
modified to target proteins and peptides to 
the cell nucleus
58, 59
. Gadolinium has been 
studied for enhanced tumour targeted 
delivery by modification of the nanoparticles 
with folate, thiamine and poly (ethylene 
glycol). Modification with folate was reported 
to enhance the recognition, internalization 
and retention of gadolinium nanoparticles in 
tumour cells
58
. Metallic nanoparticles have 
large surface area thereby incorporating a 
high drug dose. However, the toxicity of 




These include carbon nanotubes and 
fullerenes. Fullerenes are carbon allotrope 
made up of 60 or more carbon atoms with a 
polygonal structure. Nanotubes have been 
used for their high electrical conductivity and 
excellent strength
56
. These materials are 
being studied for therapeutic applications. 
Fullerenes can be functionalized for delivery 
of drugs and biomolecules across cell 
membrane to the mitochondria
58
. Carbon 
nanotubes’ unique properties including low 
cytotoxicity and good biocompatibility attract 
their use as vector system in target delivery 
of drugs, proteins and genes
58
. However, 
toxicity of carbon nanotubes is of concern
60
. 
Carbon nanotubes may cause inflammatory 
and fibrotic reactions.   
 
METHODS OF FABRICATION 
 
The method employed for the fabrication of 
nanostructures depends on the type and the 
desired properties of the nanostructure to be 
produced. Methods of preparing of polymeric 
nanoparticles have been reviewed
15, 61
 and 
they include ionic gelation, coacervation, 
solvent evaporation, spontaneous 
emulsification/solvent diffusion, salting 
out/emulsification-diffusion, supercritical fluid 
technology and polymerization. Depending 
on the materials utilized, such as 
phospholipids and glycolipids, the desired 
liposome structure can be prepared by 
sonication, electroformation, extrusion from 
diluted lamellar dispersions, high-shear 
homogenization, reverse-phase evaporation, 
gel exclusion chromatography, freeze-
lyophilization, calcium-induced fusion, 




Syntheses of dendrimers include the use of 
Tomalia’s divergent growth approach, 
convergent growth approach, and orthogonal 
coupling strategy 
26, 66, 67
, while solid lipid 
nanoparticles are prepared by high shear 
homogenization, ultrasound dispersion 
technique, high pressure homogenization, 
solvent emulsification/evaporation, 




Methods of preparing polymeric micelles 
include dialysis, solution-casting, direct 
dissolution, 
70,71
 while nanocapsules are 
prepared by microemulsion, miniemulsion 
polymerization and interfacial polymeri-
zation
43,72
. Nanoemulsions are prepared by 




nanoparticles are produced by template 
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synthesis
74
, hot pressing technique
75
 and by 




Metallic nanoparticles are synthesized by gas 
phase deposition and electron beam 
lithography. However, co-precipitation gives 
appreciable control of size, composition and 
sometimes, shape of the nanoparticles
77
. 
Gold nanoparticles are prepared in organic 
solvents (Brust-Schiffrin method), and also by 
chemical reduction of chloride precursor in 
aqueous conditions (Turkevich method)
78
 
Carbon nanomaterials are prepared by 
template synthesis
79
, the carbon-arc 
discharge technique, catalytic chemical 




CHALLENGES OF NANO DRUG 
DELIVERY 
 
Although nanotechnology in drug delivery has 
been successful, as evidenced by some nano 
drug products in the market, not all 
approaches have met with the same success. 
New nanomaterials being developed come 
with challenges which have to be 
surmounted. However some of the 
challenges encountered have been and are 
still being tackled by modification of the 
physicochemical characteristics of the 
nanomaterials to improve on properties such 
as long circulation in the blood, increased 
functional surface area, protection of 
incorporated drug from degradation, crossing 
of biological barriers and site-specific 
targeting.   
 
Another challenge of research and 
development (R&D) of nanomaterials for drug 
delivery is large scale production. There is 
always a need to scale up laboratory or pilot 
technologies for eventual commercialization. 
A number of nano drug delivery technologies 
may not be scalable due to the method and 
process of production and high cost of 
materials employed. The challenges of 
scaling up include low concentration of 
nanomaterials, agglomeration and the 
chemistry process – it is easier to modify 
nanomaterials at laboratory scale for 
improved performance than at large scale. 
Maintaining the size and composition of 
nanomaterials at large scale is also a 
challenge. 
 
Despite the number of patents for nano drug 
delivery technologies, commercialization is 
still at its early stage. This is partially due to 
the fact that most of the research studies in 
nano drug delivery are carried out by 
researchers in academia. Therefore, for 
these technologies to get to the market there 
has to be increased partnership with the 
pharmaceutical companies. Unfortunately, a 
number of the major pharmaceutical 
industries are yet to consider nanotechnology 
as one of their priorities
82
 due to lack of 
regulatory guidelines and challenges of 
scaling up. . However, it is envisaged that 
with the expiration of more patents and 
market loss, more pharmaceutical industries 
will take up the production of nano drug 
products in order to compete favourably.  
 
Advances in nano drug delivery technology 
also provide new challenges for regulatory 
control. There is an increasing need to have 
regulations that would account for 
physicochemical and pharmacokinetic 
properties of nano drug products, which are 
different from conventional drug products. 
The United States’ Food and Drug 
Administration (FDA) and the European 
Medicines Evaluation Agency (EMEA) have 
taken the initiative to identify some possible 
scientific and regulatory challenges.
82
 
Furthermore, the International Organization 
for Standardization has set up a technical 
committee (TC 229) for the field of 
nanotechnologies to develop standards 
pertaining to terminology and nomenclature; 
measurement and characterization; and 
health, safety and environment amongst 
other standards. These standards are still 




With increased R&D work on nano drug 
delivery, emerges concerns about the safety 
of the nanotechnologies in humans. Some of 
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the nanomaterials are biodegradable while 
some are not; furthermore, the side effects of 
the by-products present a huge concern. 
Materials which may be safe at macroscale 
may not be at nanoscale since there may be 
change in physicochemical characteristics at 
nanoscale. These nanomaterials may not 
clear completely from the body and their 





Safety and possible impact nanomaterials 
should not be considered for the patient 
population alone but also for the entire 
manufacturing and disposal processes. 
Conventional safety measures in a 
pharmaceutical factory may not be 
appropriate for the development and 
fabrication of nanomaterials. Also extra 
measures are to be taken to protect the 
environment from increased envisaged 
negative impacts of nanomaterials. 
 
Although reduced cost to the patients is 
envisaged to be one of the advantages of 
nanotechnology since fewer materials are 
expected to go into production as compared 
to bulk production; it is doubtful if this will be 
so, as successful commercialization will be 
expensive. There is also the general public 
reluctance to embrace nanotechnology based 
on the unavailability of documented safety 
guidelines. However, despite these 
challenges, nano drug delivery is a 
development that cannot be ignored and so 
the challenges will be tackled with time.  
 
Commercially available nano drug 
delivery systems 
 
Despite the challenges which include the 
huge volume of expenditure involved and the 
regulatory stages (preclinical and clinical 
stages – Phases 1 - 4) which are mandatory 
in order to obtain regulatory approval before 
a drug can get into the market, some nano 
drug delivery systems have made it to the 
market. Table 1 shows the list of some of 





The increasing awareness and R&D in the 
area of nano drug delivery would continue to 
change the whole concept of medicines 
including aspects such as product 
characteristics, bioavailability, pharmacokine-












Figure 1: Illustration of some nanostructures A) Spherical polymeric nanoparticle; B) Liposome; C) 
Solid lipid nanoparticles – solid lipid enclosed within; D) Nanoemulsion – liquid enclosed within; E) 
Nanocapsule – hollow; F) Carbon nanotube; G) Dendrimer; I) Polymeric micelle. 
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Enzon Pharmaceuticals Inc., 
Bridgewater, NJ, USA 
 
 Onscaspar L-asparaginase Acute 
lymphoblastic 
leukaemia 
Enzon Pharmaceuticals Inc., 
NJ, USA 
 Copaxone Glatiramer Acetate Relapsing-remitting 
multiple sclerosis 
Teva Pharmaceuticals, Tikva, 
Isreal 
 Macugen Pegaptanib 
Sodium 




Nektar Therapeutics, San 
Carlos, CA, USA; OSI 
Pharmaceuticals, Melville, NY, 
USA  
 Pegasys Pegylated 
interferon alfa-2a 
Hepatitis C Nektar Therapeutics, CA, USA  
 Neulasta Pegfilgrastim Neutopenia Nektar Therapeutics, CA, USA; 
Amgen Inc, Thousand Oaks, 
CA, USA 
 PEG-INTRON Peginterferon alfa-
2b 
Hepatitis C Nektar therapeutics, CA, USA  
 Somavert Pegvisomant Acromegaly Nektar therapeutics, CA, USA 
Liposomes Abelcet Amphotericn B Fungal infections Enzon Pharmaceuticals Inc., 
Bridgewater, NJ, USA 
 Depocyt Cytarabine Lymphomatous 
meningitis 
Enzon Pharmaceuticals Inc., 
NJ, USA 
Liposomes AmBisome Amphotericn B Fungal infections Gilead Sciences Inc., Foster 
City, CA, USA 
 Daunoxome Daunorubicin Kaposi’s sarcoma Gilead Sciences Inc., CA, USA 
 Myocet Doxorubicin Advanced breast 
cancer  





Hepatitis A virus 
Hepatitis A  
 
Berna Biotech, Bern, 
Switzerland 







Berna Biotech, Bern, 
Switzerland 
 DepoDur Morphine Analgesia EKR Therapeutics, Bedminster, 
NJ, USA 
 Visudyne Verteporfin Age-related 
macular 
degeneration 
QLT Inc., Vancouver, British 
Colombia, Canada; Norvatis, 
Basel, Switzerland 
 Doxil Doxorubicin Ovarian cancer and 
Kaposi’s sarcoma 
Ortho Biotech, Bridgewater, NJ, 
USA 
 Caelyx Doxorubicin Ovarian cancer, 
Kaposi’s sarcoma 
& breast cancer 
Schering-Plough, Kenilworth, 
NJ, USA 
 Estrasorb Estradiol Menopausal – Hot 
flushes 
Novavax, Rockville, MD, USA 




Abbott Laboratories, IL, USA 




Boehringer Ingelheim GmbH, 
Ingelheim, Germany 









Genexol-PM Paclitaxel Cancer 
chemotherapy 
Samyang Pharmaceutical, 
Daejeon City, Korea 
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Elan Corporation, Dublin, 
Ireland; Wyeth Pharmaceutical , 
Madison, NJ, USA 
 Emend Aprepitant Antiemetic Elan Corporation, Dublin, 
Ireland; Merck and Co., Inc. 
Whitehouse Station, NJ, USA 
 Tricor fenofibrate Hyperlipidemia Elan Corporation, Dublin, 
Ireland; Abbott Labs, Illinois, 
USA 
 Megace Megestrol acetate Anorexia, Cachexia Elan Corporation, Dublin, 
Ireland; Par Pharmaceuticals, 
Woodcliff Lake, NJ, USA 
Protein (albumin) 
nanoparticles 
Abraxane Paclitaxel Metastatic breast 
cancer 
Abraxis BioScience, Los 
Angeles, CA, USA;  Astra 
Zeneca, London, UK 
Lipid colloidal 
dispersion 




as well as animal and plant diseases. This in 
itself poses emormous chalemges to the 
formulation scientist who has to keep abreast 
of rapid developments in this field. A whole 
segement of R & D has opened up, posing 
great challenges to equipment 
manufacturers, material scientists, 
pharmaceutical researchers, and regulatory 
agencies. It is anticipated that better 
understanding and application of 
nanotechnology for effective drug delivery 
would ultimately enhance efficacy of 
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